Finally, while DEFA6 has been proposed as a potential biomarker in CRC, its specificity and sensitivity are demonstrated to be inferior to those of carcinoembryonic antigen [45], underscoring the need for careful interpretation regarding the clinical utility of DEFA family members. The gene discussed is CEACAM5; the disease is colorectal carcinoma.